Reader sentiment, not investment advice. One vote per visitor; click again to change it.
SMMT last changed hands at $17.08 (up 0.98%). At $13.62B, Summit Therapeutics is ranked #716 by size among the 800 stocks on BeStock.
Over the past 52 weeks it has traded between $12.07 and $29.23, so it sits 41.6% below the top of that range.
15 analysts follow the stock and the average call is "buy". The mean target, $29.58, sits 73.2% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 800 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
15 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
SMMT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $29.58, 73.2% above today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$17.08 is the latest print for SMMT, a move of +0.98% against yesterday's close of $16.91. Today's low and high so far: $16.59 and $17.18.
Equity value comes to $13.62B at the current price. By that measure it is number 716 of the 800 names in our coverage.
The year's floor is $12.07 and the ceiling $29.23. Shares are 41.6% away from that ceiling.
Our data shows no dividend paid by Summit Therapeutics over the trailing twelve months.
Of 15 analysts, 67% say buy, 27% hold and 7% sell. Price targets average $29.58, with the most cautious at $9.80 and the most optimistic at $43.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on SMMT.